Shares of Sanofi (NASDAQ:SNY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $69.00.
Several equities research analysts have recently issued reports on the company. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 29th. HSBC began coverage on Sanofi in a research note on Friday, July 14th. They issued a “buy” rating on the stock.
Institutional Trading of Sanofi
Sanofi Price Performance
Shares of NASDAQ SNY opened at $53.13 on Monday. The firm’s 50 day simple moving average is $52.91 and its 200-day simple moving average is $53.66. Sanofi has a 12 month low of $36.91 and a 12 month high of $57.82. The stock has a market capitalization of $134.14 billion, a price-to-earnings ratio of 18.20, a PEG ratio of 1.60 and a beta of 0.56. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.21 and a quick ratio of 0.81.
Sanofi (NASDAQ:SNY – Get Free Report) last issued its earnings results on Friday, July 28th. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.07. Sanofi had a net margin of 16.07% and a return on equity of 27.94%. The company had revenue of $10.85 billion for the quarter, compared to the consensus estimate of $11.47 billion. Analysts expect that Sanofi will post 4.47 EPS for the current year.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
- Five stocks we like better than Sanofi
- Large Cap Stock Definition and How to Invest
- MarketBeat Week in Review – 8/28 – 9/1
- Insider Trades May Not Tell You What You Think
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- How to Choose Top Rated Stocks
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.